New NASH drug shows promise in early trial
Disease control
Completed
This study tested an experimental drug called HPG1860 in 89 adults with NASH, a serious liver disease linked to obesity. Participants received one of three doses of the drug or a placebo for 12 weeks. The main goals were to check safety and see if the drug could reduce liver fat.…
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC